[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112019005224A2 - forma de dosagem para alívio prolongado - Google Patents

forma de dosagem para alívio prolongado

Info

Publication number
BR112019005224A2
BR112019005224A2 BR112019005224A BR112019005224A BR112019005224A2 BR 112019005224 A2 BR112019005224 A2 BR 112019005224A2 BR 112019005224 A BR112019005224 A BR 112019005224A BR 112019005224 A BR112019005224 A BR 112019005224A BR 112019005224 A2 BR112019005224 A2 BR 112019005224A2
Authority
BR
Brazil
Prior art keywords
dosage form
pharmaceutically acceptable
acceptable salt
dextromethorphan
analgesic
Prior art date
Application number
BR112019005224A
Other languages
English (en)
Inventor
Nicholas Carr Andrew
Ludher Baltej
Anness Daren
BALAN Guhan
Richard Entwisle John
E Clark Jonathan
Edward Stella Mark
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR112019005224A2 publication Critical patent/BR112019005224A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uma forma de dosagem com uma primeira porção e uma segunda porção. a primeira porção pode ser uma porção de liberação imediata e pode compreender um analgésico, que pode ser naproxeno ou naproxeno de sódio. a segunda porção pode ser uma porção de liberação prologada e pode compreender pseudoefedrina ou um sal farmaceuticamente aceitável da mesma e/ou dextrometorfano ou um sal farmaceuticamente aceitável do mesmo. a forma de dosagem pode compreender opcionalmente um agente estabilizante. a forma de dosagem pode ser adaptada para manter uma quantidade terapeuticamente eficaz de analgésico, pseudoefedrina, ou um sal farmaceuticamente aceitável da mesma, e/ou dextrometorfano, ou um sal farmaceuticamente aceitável do mesmo, durante ao menos oito horas.
BR112019005224A 2016-09-26 2017-09-25 forma de dosagem para alívio prolongado BR112019005224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662399511P 2016-09-26 2016-09-26
PCT/US2017/053157 WO2018058009A1 (en) 2016-09-26 2017-09-25 Extended relief dosage form

Publications (1)

Publication Number Publication Date
BR112019005224A2 true BR112019005224A2 (pt) 2019-06-11

Family

ID=60002143

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005224A BR112019005224A2 (pt) 2016-09-26 2017-09-25 forma de dosagem para alívio prolongado

Country Status (10)

Country Link
US (2) US10576041B2 (pt)
EP (1) EP3515413B1 (pt)
CN (1) CN109789101A (pt)
AU (1) AU2017331369B2 (pt)
BR (1) BR112019005224A2 (pt)
CA (1) CA3038263C (pt)
MX (1) MX2019003039A (pt)
PL (1) PL3515413T3 (pt)
RU (1) RU2019109695A (pt)
WO (1) WO2018058009A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018058009A1 (en) 2016-09-26 2018-03-29 The Procter & Gamble Company Extended relief dosage form
IL309902A (en) 2018-06-26 2024-03-01 Landa Corp Ltd Part for intermediate transfer to a digital printing system
CA3201462A1 (en) 2020-11-13 2022-05-19 Bayer Healthcare Llc Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
ES2179075T3 (es) * 1993-06-04 2003-01-16 Warner Lambert Co Preparaciones que contienen dioxido de silicio para mejorar su sabor.
AU7604094A (en) 1993-09-07 1995-03-27 Procter & Gamble Company, The Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US5859060A (en) 1997-01-15 1999-01-12 Platt; Chris Timed release tablet comprising naproxen and pseudoepherine
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
EP1107740A4 (en) * 1998-08-25 2002-03-06 Platt Chris SLOW RELEASE TABLET COMPRISING NAPROXENE AND PSEUDOEPHEDRINE
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
WO2003026624A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
TWI313598B (en) 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
EP1697481A2 (en) * 2003-12-09 2006-09-06 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
DE102004045037A1 (de) 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US8162276B2 (en) 2008-09-29 2012-04-24 Clipsy, Llc Rotary joint assembly and combination clip-hook and jewelry piece employing the same
US8252330B2 (en) 2009-01-05 2012-08-28 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
WO2010078542A1 (en) 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
WO2012112437A1 (en) * 2011-02-14 2012-08-23 The Procter & Gamble Company Filmcoated solid dosage forms comprising honey in the coating
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
WO2018058009A1 (en) 2016-09-26 2018-03-29 The Procter & Gamble Company Extended relief dosage form

Also Published As

Publication number Publication date
RU2019109695A3 (pt) 2020-10-26
EP3515413B1 (en) 2023-08-16
RU2019109695A (ru) 2020-10-26
EP3515413A1 (en) 2019-07-31
US20200113841A1 (en) 2020-04-16
MX2019003039A (es) 2019-07-08
WO2018058009A1 (en) 2018-03-29
CA3038263C (en) 2022-04-05
US20180085317A1 (en) 2018-03-29
CA3038263A1 (en) 2018-03-29
US10576041B2 (en) 2020-03-03
CN109789101A (zh) 2019-05-21
US11433030B2 (en) 2022-09-06
PL3515413T3 (pl) 2023-11-13
AU2017331369B2 (en) 2019-11-21
AU2017331369A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
BR112020019875A8 (pt) composições tópicas para alívio da dor
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CL2013000477A1 (es) Formulacion farmaceutica oral de liberacion inmediata que comprende nalbufina o una sal de la misma, y al menos, un soporte de granulacion hidrofilo, un aglutinante hidrofilo y un lubricante, util para el tratamiento del dolor y la dependencia a los opioides.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
BR112019005224A2 (pt) forma de dosagem para alívio prolongado
CL2008003006A1 (es) Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa.
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?
BR112015021480A2 (pt) soluções de hidromorfona intratecais tendo estabi-lidade melhorada
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
UY31826A (es) Compuesto peptídico y su uso
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
BR112015012497A2 (pt) combinações farmacêuticas
BR112019022459A2 (pt) Agente terapêutico para câncer no sangue
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.
BR112021019630A2 (pt) Composição farmacêutica
BR112018002138A2 (pt) composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões
BR112018068155A2 (pt) composição farmacêutica de liberação prolongada que compreende cisteamina ou sais da mesma
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements